In PARKINSON'S DISEASE Celance reduces performance fluctuations¹, offering patients sustained symptom control and improved quality of life².

Which may explain why it is prescribed with confidence by so many doctors.
Contents

Editorial
547 The relationship between impairment and disability
   J. R. F. Gladman

549 News and reviews

Research papers
551 Autonomic dysfunction in elderly bedfast patients
   M. Kibara, M. Takahasbi, K. Nishimoto, K. Okuda, T.-A. Matsui, T. Yamakawa and
   A. Okumura

557 Extrapyramidal signs in cognitively intact elderly people
   R. Prettyman

561 The effect of an enhanced infection-control policy on the incidence of Clostridium
difficile infection and methicillin-resistant Staphylococcus aureus colonization in acute
elderly medical patients
   S. P. Stone, V. Beric, A. Quick, A. A. Balestrini and C. C. Kibbler

569 Risk-factor assessment for falls: from a written checklist to the penless clinic
   C. A. E. Dyer, C. L. Watkins, C. Gould and J. Rowe

573 Prevalence of diabetes mellitus in elderly people in Canada: report from the Canadian
   Study of Health and Aging
   K. Rockwood, M.-H. Tan, S. Phillips and I. McDowell

579 Are rates of ageing determined in utero?
   A. Albie Sayer, C. Cooper, J. R. Evans, A. Rauf, R. P. L. Wormald, C. Osmond and
   D. J. P. Barker

585 Mortality in elderly men and women in a Swedish municipality
   T. M. Gustafsson, D. G. L. Isacson and M. Thorslund

595 The impact of multiple impairment on disability in community-dwelling older people
   G. I. J. M. Kempen, L. M. Verbrugge, S. S. Merrill and J. Ormel

605 The description of activities of daily living in five centres in England and Wales
   The Medical Research Council Cognitive Function and Ageing Study

615 Validity of Direct Assessment of Functional Status as a tool for measuring Alzheimer's
disease severity
   O. Zanetti, G. B. Frisoni, L. Rozzini, A. Bianchetti and M. Trabuccbi

623 Factors influencing decisions about donation of the brain for research
   M. Stevens

631 A prospective study of dementia with Lewy bodies
   C. G. Ballard, J. O'Brien, K. Lowery, G. A. Ayre, R. Harrison, R. Perry, P. Ince, D. Nell and
   L. G. McKeith

637 The relationship between difficulties in feeding oneself and loss of weight of nursing home
   patients with dementia
   A. M. M. Berkbout, H. J. M. Cools and H. C. van Houwelingen

643 Low activity of superoxide dismutase and high activity of glutathione reductase in
   erythrocytes from centenarians

Case report
649 An unusual case of breast cancer relapse after 30 years of disease-free survival
   D. Dal Lago, G. Villa, R. Miglioli, G. Annoni and C. Vergani

Hobby horse
651 Caring for carers
   W. J. MacLennan

Letters to the Editor
653 Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in
   elderly patients
   A. Farnsworth
Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease
F. Lebert, C. Mouly and F. Pasquier

Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people
M. W. Cooper and T. J. Hendra

Considering the 'do not resuscitate' decision
N. Page and D. Morris

Lifestyle and medication compliance in elderly patients
W. von Renteln-Kruse; D. Minors, J. Waterhouse, G. Atkinson and Patrick Rabbitt

Urine collection and culture in elderly people
J. E. Clague and M. A. Horan

Acute medical bed usage by nursing-home residents
T. Beringer and P. Flanagan

Book reviews

Please visit the journal's World Wide Web site at http://www.oup.co.uk/ageing
Good night!

Good day

For patients with advanced Parkinson's disease Cabaser is the only dopamine agonist that, from a single daily dose, offers continuous 24 hour activity. Cabaser provides:

- Through-the-night effectiveness to relieve nocturnal immobility and morning dystonia
- Early morning improvement in mobility and functioning, even before morning medication is taken coupled with significant reduction of 'off' time and significant improvement in 'on' time, right around the clock.

ONCE A DAY

24 hour relief of symptoms in fluctuating Parkinson's disease

Abbreviated Prescribing Information

Presentation: Cabaser tablets. Containing 1, 2 or 4 mg cabergoline. Uses: The treatment of symptomatic Parkinson's disease in patients affected by 'on-off' mobility problems with daily fluctuations in motor performance; improvement of motor deficit has been demonstrated while permitting a substantial decrease in levodopa dose. Dosage and Administration: Adults and elderly patients: The recommended therapeutic dosage is 2 mg/day as an advanced therapy to levodopa given as a single daily oral dose. Doses should be titrated slowly against efficacy and tolerability. A starting dose of 1 mg/day is recommended; the dosage of concurrent levodopa may be gradually decreased, while the dose of Cabaser is increased. In view of the long half-life of the compound, the dose may be increased in gradual weekly or bi-weekly intervals by increments of 0.5-1.0 mg, up to optimal doses. Use in Children: not recommended. Contra-indications, warnings etc.

- Contra-indications: Hypersensitivity to any active or inert. Warnings: In patients with severe hepatic insufficiency the dose should be reduced accordingly. Cabaser should be given with caution to patients with a history or clinical symptoms of respiratory disorders linked to fibrotic tissue degeneration. Renal insufficiency has not been shown to modify Cabaser kinetics. Caution is advised in patients suffering from severe cardiovascular disease, Raynaud's syndrome, preeclampsia, hemorrhoidal bleeding or a history of major psychiatric illness. In cases of unexplained high ESR, or evidence of respiratory symptoms, a chest X-ray is recommended to exclude pleural effusion/fibrosis. Symptomatic hypertension can occur following administration of Cabaser; particular attention should be paid when administering Cabaser concomitantly with other drugs known to lower blood pressure. Patients should be cautioned about engaging in activities requiring rapid and precise responses, e.g. driving or operating machinery. Drug Interactions: No pharmacokinetic interaction with levodopa or selegline has been observed in clinical studies in Parkinsonian patients. Concomitant use of other oral dopamnergic drugs with Cabaser is not recommended. Cabaser should not be administered concurrently with drugs which have dopamine antagonist activity since this may reduce Cabaser's efficacy. Cabaser should not be used in association with macrolide antibiotics since systemic bioavailability of Cabaser and adverse effects could increase. The effects of alcohol on overall tolerance of Cabaser are currently unknown. Pregnancy and lactation: Based on limited clinical experience, cabergoline does not appear to be associated with an increased risk of abortion, premature delivery, multiple pregnancy or congenital abnormalities. As a precautionary measure, it is recommended that women seeking pregnancy discontinue Cabaser eight weeks before intended conception. In order to prevent possible fetal exposure to the drug if conception occurs during therapy, treatment is to be discontinued as soon as pregnancy is confirmed. Do not use in nursing mothers as lactation may be inhibited, no information on the excretion of cabergoline in mother's milk is available. Undesirable effects: Events most frequently reported in clinical studies were dyskinesia, hallucinations, tachycardia or confusion. Other events include nausea, vomiting, dyspepsia and gastritis, as well as dizziness and hypotension. Symptomatic placebo equivalent is low, but appears to be higher in these cases discontinuation of Cabaser is expected to lead to immediate:

References:
Geriatric Programs and Departments Around the World

J.P. Michel, MD, L. Z. Rubenstein, MD, Editors

A compendium of descriptive and analytic papers covering a spectrum of geriatric systems, and organization and practice centers around the world including those of 11 European countries, China, USA, Ukraine, Israel, and Canada.

Contents: Part I: Place of Geriatrics in the Health Care System
Part II: Geriatric Medicine and Gerontology Centers
Part III: Geriatric Programs: Alzheimer Units, Home Care, Emergency, Palliative Medicine

1998 496pp 0-8261-1198-X softcover $45.95 (outside US $54.80)

Research and Practice in Alzheimer’s Disease

Bruno J. Vellas, J. L. Fitten, Editors

Advances on the latest research findings about Alzheimer’s Disease and related dementias continue to be of the utmost importance to practitioners as well as the general public. In this impressive international volume, Bruno Vellas has assembled the most important researchers in the field to present their latest research results. Topics range from biological advances to behavioral outcomes, services implications, and much more.

1998 384pp 0-8261-1194-7 softcover $46.95 (outside US $51.80)

Journal of Nutrition, Health, and Aging

B. Vellas, W.C. Chumlea, D. Lanzmann Petithory, Editors

The NEW forum for scientific and clinical studies of nutrition’s effect on health development throughout the lifespan. Special focus on: chronic disease; the development of health capital during childhood, adulthood, and old age; successful aging; and population diversity.

Vol. 2, 1998 / Vol. 3, 1999 (3 issues) • ISSN 1279-7707
Individual: ☐ $80 / 1 yr. ☐ $135 / 2 yrs. Institution: ☐ $120 / 1 yr. ☐ $210 / 2 yrs.

SERDI, 320, Rue Saint-Honoré, F-75001 Paris
FAX: (33) 5 61 75 11 28 • E-mail: 100775.1315@compuserve.com • www.serdi-fr.com

SPRINGER PUBLISHING COMPANY
536 Broadway, New York, NY 10012 • (212) 431-4370 • Fax: (212) 941-7842
Email: www.springerpub@spacelab.net • www.springerpub.com
With new Exelon, you can now help treat the symptoms of people with mild to moderately severe Alzheimer’s disease.

While Exelon has not been shown to affect the disease process, six-month trials have established its effectiveness on key areas that Alzheimer’s disease attacks - cognition, global functioning and activities of daily living.¹

For carers and family, this could mean some relief from the demands for attention; for the sufferer, it could mean life beyond Alzheimer’s.

NEW

EXELON
(rivastigmine)

Beyond cognition: improving functional ability.

EXELON Prescribing Information. Indication: Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. Presentation: Capsules containing 1.5, 3, 4.5 or 6mg rivastigmine. Dosage and Administration: Effective dose is 3 to 6mg twice a day. Maintain patients on their highest well-tolerated dose. Maximum dose 6mg twice daily. Decrease patients regularly. Initial dose 1.5mg twice daily, then build up dose, at a minimum of two week intervals, to 3mg twice daily. 4.5mg twice daily then 6mg twice daily. If tolerated well. If adverse effects or weight decrease occur, these may respond to omitting one or more doses. If persistent, daily dose should be temporarily reduced to previous well tolerated dose. Contraindications: Known hypersensitivity to rivastigmine or recipients or any other carbamate derivatives; severe liver impairment. Special Warning & Precautions: Therapy should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s disease. A caregiver should be available to monitor compliance. There is no experience of use of EXELON in other types of dementia/memory impairment. Nausea and vomiting may occur, particularly when initiating and/or increasing dose. Monitor any weight loss. Use with care in patients with Sick Sinus Syndrome, conduction defects, active gastric or duodenal ulcers, or those predisposed to ulcerative conditions, history of asthma or obstructive pulmonary disease, those predisposed to urinary obstruction and seizures. In renal and mild to moderate hepatic impairment. Titrate dose individually. Safety in pregnancy not established; women should not breastfeed. Use in children not recommended. Interactions: May exaggerate effects of succinylcholine type muscle relaxants during anaesthesia. Do not give with cholinomimetic drugs. May interfere with anticholinergic medications. No interactions were observed with digoxin, warfarin, diacepram, or fluoxetine (in healthy volunteers). Metabolic drug interactions unlikely, although it may inhibit butyrylcholinesterase mediated metabolism of other drugs. Undesirable Effects: Most commonly (25% and twice frequency of placebo): asthenia, anorexia, dizziness, nausea, somnolence, vomiting. Female patients more susceptible to nausea, vomiting, appetite and weight loss. Other common effects (≤5% and > placebo): abdominal pain, occipital trauma, agitation, confusion, depression, dizziness, dyspnea, headaches, insomnia, upper respiratory tract and urinary tract infections, increased sweating, malaise, weight loss, tremor. Rarely, angrna pectoris, gastrointestinal haemorrhage and syncope. No notable abnormalities in laboratory values observed. Package Quantities and basic NHS Price: 1.5mg x 28 = £31.50, 1.5mg x 56 = £63.00, 3mg x 28 = £63.50, 3mg x 56 = £127.00; 4.5mg x 28 = £63.50, 4.5mg x 56 = £127.00, 6mg x 28 = £127.50, 6mg x 56 = £255.00. Legal Classification: POM. Marketing Authorisation Number: 1.5mg, EU/1/98/056/001-2; 3mg, EU/1/98/056/004-5; 4.5mg, EU/1/98/066/007-8; 6mg, EU/1/98/066/010-11. Full prescribing information including Summary of Product Characteristics is available from Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.


Date of preparation: August 1998.

Code No. EXE 98/63

EXELON INFORMATION SERVICE: PHONE FREE 0808 100 8484

NOVARTIS
Changi General Hospital (CGH) is a multi-disciplinary 800-bed government restructured hospital in Singapore. The hospital has 23 wards, medical and surgical intensive care units and offers a comprehensive range of specialised medical services. Located in the eastern sector of Singapore, CGH is poised to be a key healthcare provider for about 800,000 residents. We are recruiting highly competent and caring medical professionals to join us as:

**SENIOR CONSULTANTS/CONSULTANTS/SENIOR REGISTRARS**

Candidates must possess a basic medical degree that is registrable with Singapore Medical Council, and MRCP(UK) or be American Board Certified in Geriatric Medicine. In addition, applicants for the post of Consultants should have more than 5 years' clinical experience in Geriatric Medicine and those applying for the post of Senior Registrar should have completed 3 years' specialty training.

**Annual Salary Range (inclusive of specialist allowance)**

<table>
<thead>
<tr>
<th>Position</th>
<th>Salary Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senior Consultant</td>
<td>S$162,680 - S$298,800</td>
</tr>
<tr>
<td>Consultant</td>
<td>S$123,200 - S$192,000</td>
</tr>
<tr>
<td>Senior Registrar</td>
<td>S$80,080 - S$109,000</td>
</tr>
</tbody>
</table>

**Other Benefits**

- Variable bonus depending on company's performance
- Relocation expenses inclusive of a one-time settling-in allowance
- Monthly housing allowance
- Vacation leave
- Medical and hospitalisation leave and benefits
- Life and accident insurance coverage

**Contract**

Contracts are for a period of 3 years with option for renewal.

Applications including curriculum vitae, names of 2 professional references, present and expected salary and contact number together with a non-returnable photograph should be sent to:

The Director, Human Resource
Changi General Hospital
2, Simei Street 3
Singapore 529889
Republic of Singapore
Fax: 65 - 787 0876
E-mail: tphhrd@pacific.net.sg

---

**OXFORD JOURNALS ADVERTISING**

To advertise in this publication contact
Peter Carpenter

**PRC ASSOCIATES**

Advertisement Managers

THE ANNEKE, FITZNELLS MANOR
CHESSINGTON ROAD, EWELL VILLAGE
SURREY KT17 1TF, UK

TELEPHONE: +44 (0)181-786 7376 FAX: +44 (0)181-786 7262
EMAIL: prcassoc@compuserve.com
Age and Ageing

Editor

G. P. Mulley (Leeds)

Editorial Board

Chairman M. Hildick-Smith (Canterbury),
Features Editor J. F. Potter (Leicester),
Abstracts Editor J. R. F. Gladman (Nottingham),
Associate Editor F. I. Caird (Oxford),
Book Review Editor J. R. Playfer (Liverpool),
A. K. Banerjee (Bolton), T. B. L. Kirkwood (Manchester), I. McKeith (Newcastle), W. J. MacLennan (Edinburgh), B. O. Williams (Glasgow).

International Advisory Board

G. Abate (Italy), W. H. Barker (USA), E. Barrett-Connor (USA), P. P. Barry (USA), G. A. Broe (Australia), A. J. Campbell (New Zealand), S. A. Duursma (Netherlands), J. B. Halter (USA), A. Hofman (Netherlands), R. L. Kane (USA), K. Laake (Norway), L. A. Lipsitz (USA), G. M. Martin (USA), J.-P. Michel (Switzerland), J. G. Ouslander (USA), C. Powell (Canada), K. Rockwood (Canada), M. Schroll (Denmark), K. I. Shulman (Canada), B. Steen (Sweden), T. Vandewoude (Belgium), T. J. Wells (USA), J. Woo (Hong Kong), T. T. Yoshikawa (USA).

Editorial Office

Editorial consultant: R.L. Reid
Editorial assistant: A.L. Wills

Please address editorial queries to Mrs A.L. Wills, Age and Ageing Editorial Office, Elderly Services Directorate, St James’s University Hospital, Leeds LS9 7TF, UK. Tel/fax (+44) 113 2469275. E-mail: aa@age-and-ageing.demon.co.uk.

Age and Ageing is an international journal publishing refereed original articles and commissioned reviews on geriatric medicine and gerontology. Its range includes research on ageing and the clinical, epidemiological and psychological aspects of later life. The journal is listed in Index Medicus, Current Contents, Life Sciences/Clinical Practice, Excerpta Medica and CABS (Current Awareness in Biological Sciences).

Advertising enquiries should be made to Peter Carpenter, PRC Associates, The Annexe, Fitznells Manor, Chessington Road, Ewell Village, Surrey KT17 1TF, UK. Tel. +44 181-786-7376.

Books for review should be sent to Dr J. R. Playfer, Book Review Editor, Age and Ageing, Department of Geriatric Medicine, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK.

Subscriptions Age and Ageing is published six times a year, January–November, at an annual subscription of £140.00 (UK and Europe) and US$235.00 (rest of world). Please add sales tax to the prices quoted. Prices include postage by surface mail or for subscribers in the USA and Canada by Airfreight, or for Japan, Australia, New Zealand and India by Air Speeded Post. Airmail rates are available on request. Single issues: £30.00 (UK and Europe) and US$50.00 (rest of world). Back issues are sold at the current single issue rate, and complete back volumes are sold at the current single issue rate multiplied by the number of issues in the volume. Payment is required with all orders, and subscriptions are accepted and entered by the volume/s. Payment may be made by the following methods: cheque (made payable to Oxford University Press); National Girobank (account 500 1056); credit card (Mastercard, Visa, American Express, Diners, JCB); UNESCO Coupons; direct debit (details on request). Bankers: Barclays Bank plc, PO Box 333, Oxford, UK, code 20-65-18, account number 00715654. Please send orders and requests for sample copies to the Journals Subscriptions Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Tel. +44 1865 267907. Telefax +44 1865 267485.

Age and Ageing (ISSN 0002-0729) is published by Oxford University Press, Oxford, UK. Age and Ageing is distributed by M.A.I.L. America, 2323 Randolf Avenue, Avenel, New Jersey, NJ 07001, USA. Periodical postage paid at Rahway, New Jersey, USA and additional entry points.

US POSTMASTER: send address changes to Age and Ageing, c/o M.A.I.L. America, 2323 Randolf Avenue, Avenel, New Jersey, NJ 07001, USA.

© 1998 British Geriatrics Society

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without either the prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those in US/Canada not registered with CCC, articles can be obtained by fax in 48 hours by calling: WISE for Medicine™ 1-800-667-WISE.

Typeset and printed by the Alden Group, Oxford.
Information for contributors

Age and Ageing is an international journal which presents an eclectic view of ageing and of sickness, disability and health in later life.

The target readership includes clinicians, who wish to be informed about new developments in medicine and related fields (including sociology, psychology, ethics, economics and politics), scientists (including biological gerontologists and social scientists), and other professionals who work in subjects related to the medicine of later life.

The journal is a forum for the dissemination and integration of knowledge. It aims to heighten understanding, highlight gaps in our knowledge — thereby promoting further research — and improve clinical care by promoting good practice and identifying needless, inappropriate and harmful activities.

Subjects covered include epidemiology, gerontology, physiology, sociological aspects of ageing, psychology, clinical trials, service delivery, pharmacology, and hospital as well as community care. We aim to publish well-written clinical and scientific research reports of the highest quality, which are original and relevant. Clinical trials are welcome. We also publish papers reporting negative results and meta-analyses. We are pleased to receive authoritative reviews and commentaries, which might be critical or constructive, selected case reports, provocative and lively letters, teaching points and other special pieces.

As well as presenting articles on the science, art and craft of gerontology and geriatric medicine, Age and Ageing wishes to stimulate, entertain and inform by including photographs of older people and age-related topics, aphorisms, poems and prose.

Submission of manuscripts Contributions and correspondence should be sent to Professor G. P. Mulley, Editor, Age and Ageing, Elderly Services Directorate, St James’s University Hospital, Leeds LS9 7TF, UK. Tel/fax: (+44) 113 2469275. Email: age-and-ageing.demon.co.uk.

Submissions to Age and Ageing should not have been previously published (except as an abstract, in which case details should be given). Similarly, the article should not be under consideration by another journal.

All authors must give signed consent to publication. (Credit for authorship requires important contributions to designing and doing the study, analysing and interpreting the data, and writing the article.)

Scientific research articles should be no longer than 2000 words (please give a word count). Submissions may be modified or shortened by the Editor before acceptance for publication.

Manuscript preparation Type all manuscripts in double spacing and number each page. The first page should include all authors’ full names (clearly indicating which is the family or surname); the name of the centre where the work was done; address of each author; telephone, fax and e-mail details. There is no need to include academic awards but do include titles.

As articles are sent anonymously to referees, a page with the title only should be included.

Please send four copies (one for each reviewer and one for the Editor). Keep a copy yourself. Also include four copies of any figures or photographs. Do not send a disk until you have been informed that your paper has been accepted.


Please also include: (i) a structured abstract — headings might include background, objective, design, setting, subjects, methods, results, conclusions; (ii) up to five keywords (please use terms from the Medical Subject Headings in Index Medicus); (iii) a running heading (a shortened version of the title), (iv) a Key points box with 2-5 bullet points which summarize the main messages of your paper; (v) a title for each table or figure; (vi) no more than six tables or figures; (vii) details of sources of research funding or any possible conflict of interest, and (viii) details of informed consent of patients or volunteers studied and approval of an ethics committee, where appropriate.

Authors are encouraged to supply the names and addresses of two or three potential referees, although the Editor reserves the right of final selection.

Please ensure all abbreviations are defined at first usage, scientific measurements are in SI units, and approved names are used for drugs.

Try to avoid language that might be deemed unacceptable or inappropriate (e.g. ‘older people’ is preferable to ‘the elderly; the word ‘senile’ is best avoided).

Take care with wording that might cause offence to ethnic or cultural groups.

Manuscripts not meeting these requirements may be returned to the authors for modification.

References should be numbered in order of citation and cited in the text by numbers in square brackets. They should be listed in the reference list in the form prescribed in the Uniform Requirements (giving the names and initials of all authors, unless there are more than six, when the first three should be given, followed by et al.)

Illustrations For diagrams, original artwork (black ink on white paper) is preferred, but glossy prints (not negatives or photographs) will usually be acceptable. Illustrations are best supplied larger than final printed size but lettering must be large enough to be legible after reduction. All illustrations should bear the author’s name and number of the illustration on the reverse side. Degree of magnification should be indicated where necessary. Captions should be typed on separate sheets. It is the responsibility of the author(s) to ensure that any requirements of copyright and courtesy are fulfilled in reproducing illustrations and appropriate acknowledgement included with the captions.

Review and Commentaries Before submitting a Review or Commentary, please contact the Editor or Features Editor with an outline of your plans.

Case reports Clinically interesting cases should be written in 4-600 words with no more than one figure or table. Case reports should be of conditions which provide new insight, describe rare but modifiable disorders or present new treatments or understanding. All Case reports are peer-reviewed.

Correspondence We welcome lively, provocative, stimulating and amusing letters, as well as comments on and criticisms of articles previously published in the journal. Authors may be invited to re-submit shorter versions of manuscripts for publication in this section. Letters should be double-spaced and signed. Those including original data will be sent for peer review.

Special sections We will publish a range of article types: ‘Grand round’, with a focus on common problems and discussion from members of the interdisciplinary team; ‘Letter from...’ giving details of developments in gerontology and geriatric medicine in different parts of the world; ‘Personal view’, expressing an individual opinion or approach to elderly care or biological or social gerontology; ‘Physical sign’, critically evaluating the validity and usefulness of clinical signs in geriatric medicine; ‘News and reviews’: summaries of and brief comment on interesting articles which have appeared in other journals.

Fillers We welcome photographs of older people or age-related subjects, drawings, anecdotes, aphorisms and poems on old age. Photographs should be submitted as black-and-white or colour prints. They should be unmounted and with an unmarked front surface. The subjects should sign a release form, confirming that they agree to their picture being published. It is considered to inform the subject’s family that the picture is to be printed.

Proofs are sent to authors for the correction of printer’s errors only. Authors making extensive alterations will be required to bear resulting costs.

Reprints of articles can be ordered on the form supplied which should be returned to the publishers with payment. Twenty-five offprints are supplied free to the first named author on publication.

Copyright It is a condition of publication in the journal that authors assign copyright to the British Geriatrics Society. This ensures that requests from third parties to reproduce articles are handled efficiently and consistently and will also allow the article to be as widely disseminated as possible. In assigning copyright, authors may use their own material in other publications provided that the journal is acknowledged as the original place of publication, and Oxford University Press is notified in writing and in advance.